摘要:
The present invention relates to a β3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity.
摘要:
The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity.
摘要:
The present invention relates to a β3 adrenergic receptor agonist of formula I: or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity.
摘要:
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-II3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods or using them to treat obesity and other histamine II3 receptor-related diseases.
摘要:
The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently —(C1—C7) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence —H, -halogen, or —CH3.
摘要:
The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical. compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
摘要:
The present invention relates to a β3 adrenergic receptor agonist of formula (I), wherein R is C3-C8 alkyl or (C3-C7 cycloalkyl)C1-C5 alk-di-yl: R1 is H, CN, halo; C1-C6 alkyl, C1-C4 haloalkyl, C02 R6, CONR6R6, NR6COR7, NR6R6, OR6, SR6, SOR7. S02R7 or S02NR6R6; R1a is H, halo or C1-C6 aLkyl; R2 is Hi or C1-C6 alkyl; R3 and R4 are independently H or C1-C6 alkyl R5 is hydrogen, optionally substituted phenyl or optionally substituted heterocycle; X is absent or is OCH2 or SCH2; X1 is absent or C1-C5 alk-di-yl; and X2 is absent or is O, S, NH, NHS02, S02NH or CH2; or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 deabetes and/or obesity
摘要翻译:本发明涉及式(I)的β3 N 3肾上腺素能受体激动剂,其中R是C 3 -C 8烷基或(C C 3 -C 3 - 环烷基)C 1 -C 5烷基 - 二基:R 1 H,CN,卤素; C 1 -C 6烷基,C 1 -C 4卤代烷基,C 0 sub R 6,C 6,C 6,R 6,R 6,R 6,R 6, 6,6,6,6,6,6,7, S0 i> 2 sup>或者S0< 2< 6< 6> 6< 6> R 1a是H,卤素或C 1 -C 6 -C 1-4烷基; R 2是H 1或C 1 -C 6烷基; R 3和R 4独立地为H或C 1 -C 6烷基R 5, SUP>是氢,任选取代的苯基或任选取代的杂环; X不存在或是OCH 2或SCH 2; X 1不存在或C 1 -C 5烷基 - 二基; 和X 2不存在,或者是O,S,NH,NHSO 2,SO 2 NH或CH 2, ; 或其药学盐; 其能够增加细胞中的脂肪分解和能量消耗,因此可用于治疗2型糖尿病和/或肥胖
摘要:
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases
摘要:
The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.
摘要:
The present invention discloses novel substituted azepine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such azepines as well as methods of using them to treat obesity and other histamine H3 receptor-related diseases.